Abstract

Background: Hepatitis C virus (HCV) infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC). Despite recent advances in the understanding of the biological basis of HCC development, the molecular mechanisms underlying HCV-induced HCC (HCC-HCV) remain unclear. The carcinogenic potential of HCV varies according to the genotype and mutation in its viral sequence. Moreover, regulatory pathways play important roles in many pathogenic processes. Therefore, identifying the pathways by which HCV induces HCC may enable improved HCC diagnosis and treatment.Methods: We employed a systematic approach to identify an important regulatory module in the process of HCV-HCC development to find the important regulators. First, an HCV-related HCC subnetwork was constructed based on the gene expression in HCC-HCV patients and HCC patients. A priority algorithm was then used to extract the module from the subnetworks, and all the regulatory relationships of the core genes of the network were extracted. Integrating the significantly highly mutated genes involved in the HCC-HCV patients, core regulatory modules and key regulators related to disease prognosis and progression were identified.Result: The key regulatory genes including EXO1, VCAN, KIT, and hsa-miR-200c-5p were found to play vital roles in HCV-HCC development. Based on the statistics analysis, EXO1, VCAN, and KIT mutations are potential biomarkers for HCV–HCC prognosis at the genomic level, whereas has-miR-200c-5P is a potential biomarker for HCV–HCC prognosis at the expression level.Conclusion: We identified three significantly mutated genes and one differentially expressed miRNA, all related to HCC prognosis. As potential pathogenic factors of HCC, these genes and the miRNA could be new biomarkers for HCV-HCC diagnosis.

Highlights

  • Hepatocellular carcinoma (HCC)—the second leading cause of cancer−related deaths worldwide (Merte, 1989)—is often diagnosed at an advanced stage and progresses rapidly

  • In TCGA, liver hepatocellular carcinoma (LIHC) samples are divided into two groups: the first group contains hepatitis C virus (HCV) RNA or genotype or hepatitis C antibody in the patient’s clinical information, and the other group does not; here, we named the two groups HCC-HCV and HCC

  • Further analysis showed that missense mutation, single-nucleotide polymorphisms (SNPs), and C > T accounted for the highest proportion of the variations (Figures 1B–D)

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC)—the second leading cause of cancer−related deaths worldwide (Merte, 1989)—is often diagnosed at an advanced stage and progresses rapidly. In HCC patients, early diagnosis is very important to improve their prognosis. Early clinical screening methods for HCC involve serum alpha fetoprotein (AFP) detection and liver ultrasound examination (Sato et al, 1993). As the understanding of cancer biology improves, liquid biopsy will become an increasingly useful tool for early diagnosis. Risk factors for HCC include cirrhosis, aflatoxin B intake, alcohol consumption, and hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. Few studies have been focused on the factors leading to liver cancer in HCV patients. HCV RNA, cirrhosis, and HCV genotype are thought to affect the occurrence of HCV-related liver cancer, but the involvement of these factors has not been conclusively proven. Hepatitis C virus (HCV) infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC). Identifying the pathways by which HCV induces HCC may enable improved HCC diagnosis and treatment

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call